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Abstract
Background/Purpose
Aptamers are oligonucleotide or peptide molecules that bind to a target molecule with high
affinity and specificity. The present study aimed to evaluate the target specificity and appli-
cability for in vivo molecular imaging of an aptamer labeled with a radioisotope.
Methods
The human epidermal growth factor receptor 2 (HER2/ErbB2) aptamer was radiolabeled
with 18F-fluoride. HER2-positive tumor cell uptake of the aptamer was evaluated in compari-
son to negative controls by flow cytometry and confocal microscopy. Using 18F-labeled
HER2-specific aptamer positron emission tomography (PET), in vivo molecular images of
BT474 tumor-bearing mice were taken at 60, 90 and 120 minutes after injection.
Results
In flow cytometric analysis, HER2 aptamer showed strong binding to HER2-positive BT474
cells, while binding to HER2-negative MDA-MB231 cells was quite low. Likewise, in confocal
microscopic images, the aptamer was bound to HER2-positive breast cancer cells, with min-
imal binding to HER2-negative cells. In vivo PET molecular imaging of BT474 tumor-bearing
mice revealed significant higher uptake of the 18F-labeled HER2 specific aptamer into the
tumor compared to the that of HER2-negative cell tumor(p = 0.033). HER2 aptamer was
able to preferentially bind to HER2-positive breast cancer cells both in vitro and in vivo, by
recognizing HER2 structure on the surface of these cells.
Conclusion
The 18F-labeled aptamer enabled appropriate visualization of HER2 expression by human
breast cancer cells. The results suggest that a radiolabeled HER2 aptamer could potentially
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Introduction
Aptamers, from the Latin “aptus,” meaning to fit, and the Greek “meros,” meaning region, are
single-stranded oligonucleotides ranging from 20–90 base pairs in length. Usually derived
using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) methodologies [1,
2], aptamers bind to a target molecule with high affinity and specificity [3, 4]. Hence, they are
regarded as ideal reagents for detecting and measuring expression of their target molecules.
Aptamers have several advantages over antibodies, including reduced production costs, ease of
synthesis, low toxicity, low immunogenicity, and the fact that they do not require an organism
for their production [5]. Accordingly, aptamers are relatively new reagents in the field of ther-
agnosis. Numerous aptamers have been generated against a variety of targets, such as thrombin
[6], nucleolin [7], prostate-specific membrane antigen (PSMA) [8], tenascin-C (TNC) [9], and
viral proteins [10]. In the therapeutic arena, Pegaptanib, a targeted anti-VEGF (vascular endo-
thelial growth factor) aptamer [11], was approved by the FDA for treatment of macular degen-
eration. At present, many aptamers are undergoing preclinical and clinical phase evaluation
[12], and more trials with diagnostic and therapeutic oligonucleotides are being carried out.
Consequently, there is a growing demand for feasible methods with which to evaluate and ver-
ify already developed aptamers.
HER2, a well-known oncogene, is amplified or overexpressed in approximately 15–30% of
breast cancers [13, 14]. It is strongly associated with a high incidence of disease recurrence and
poor prognosis in several cancers [15]. Two key signaling pathways activated by HER2 are the
mitogen-activated protein kinases (MAPK) pathway, which stimulates proliferation, and the
phosphatidylinositol 3 kinase–protein kinase B (PI3K–Akt) pathway, which promotes tumor
cell survival [16]. Accordingly, HER2 is regarded as an important therapeutic target in applica-
ble cancers. There are well-known therapeutic monoclonal antibodies targeting HER2, such as
trastuzumab and pertuzumab, which are clinically effective. Meanwhile, several DNA/RNA
aptamers targeting HER2 have previously been developed via conventional SELEX and cell
SELEX [17–21]. The potential pharmacological utility of a HER2 aptamer for tumor inhibition
by an endocytosis-mediated mechanism was recently reported [19].
Molecular imaging refers to noninvasive, real-time visualization of biochemical events at
the cellular and molecular level within living cells, tissues, and/or intact subjects [22]. PET is a
representative molecular imaging modality. It is a radionuclide molecular imaging technique
that enables evaluation of biochemical changes and levels of molecular targets within a living
subject. PET has excellent sensitivity and a wide range of applications in basic research and
preclinical arenas, and can easily be applied in the clinical field, owing to its negligible pharma-
cological effects. In the field of molecular imaging, the visualization of tumor targeting by apta-
mers is an emerging technique. Hicke et al. previously investigated molecular imaging using
aptamer. They conjugated 99mTc to TTA1, an aptamer for the extracellular matrix protein
tenascin-C, and obtained γ-camera images of tumors in vivo [23]. Subsequently, PET imaging
of tenascin-C with a radiolabeled single-stranded DNA aptamer was reported by Jacobson
et al [24]. To the best of our knowledge, 18F PET imaging of a HER2 aptamer in mouse model
of breast cancer has not yet been investigated.
In this study, we conjugated the radioisotope 18F to a HER2-specific aptamer in order to
validate its target specificity and utility for in vivo molecular imaging.
PET imaging of HER2 aptamer
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Materials and methods
Ethics statement
All the described procedures were reviewed and approved by the Animal Care Use Committee
at Yonsei University (IACUC 2014–0259) and were performed in accordance with the guiding
principles for the Care and Use of Laboratory Animals.
Cell culture
The HER2-positive human breast cancer cell line BT474 was used for in vitro and in vivo
experiments. As a negative control for all of the experiments, the human breast cancer cell line
MDA-MB231 was used. SK-BR3 and HS578T cells were used as positive and negative controls
to compare HER2 expression. All cell lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). The cells were maintained in minimum essential
medium supplemented with 10% fetal bovine serum and antibiotics in a humidified incubator
at 37˚C.
Cell lysis and western blotting
To extract cellular proteins, cells were incubated in cell lysis buffer (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) containing protease inhibitors on ice for 30 minutes. Cell lysates
were clarified by centrifugation at 14,000 rpm at 4˚C for 20 min. Protein concentrations were
determined via the Bradford method (Thermo Fisher Scientific, Rockford, IL, USA). For west-
ern blot analysis, 30 μg of protein extract from each sample was electrophoresed on 10%
SDS-PAGE gels and transferred to nitrocellulose membranes. The membranes were probed
with HER2 antibody (Abcam, Cambridge, MA, USA), and ß-actin antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) was used as a loading control. Signals were developed using
an ECL chemiluminescence substrate kit (Advansta, Menlo Park, CA, USA).
Annealing, and conjugation of aptamer
HER2 aptamers were purchased from Aptamer Sciences Inc. (APSCI, Pohang, Republic of
Korea) (#SH-1194-35[25]) and Bioneer (Bioneer, Daejeon, Republic of Korea) (2-2(t)[19]).
The SH-1194-35 aptamer is a modified aptamer with a 5’ amine group, which contains napthyl
nucleoside to increase affinity and serum half-life (molecular weight: 14343.07). The scrambled
random sequence was created using a random number table with a length equal to the that of
the SH-1194-35 aptamer.
The aptamer was dissolved in dH2O to a final concentration of 2 μg/μL. Aptamer was
heated and cooled to permit proper folding of their structures according to the manufacturer’s
instructions. Fluorescence-labeled single stranded DNA was purchased from Bioneer (Bio-
neer, Daejeon, Republic of Korea). Oligonucleotides were annealed at their calculated melting
temperatures (Tm’s) and allowed to slowly cool to room temperature. The secondary folding
structure and Tm of each oligonucleotide were calculated on the basis of its lowest free energy
structure, using Oligocalc web servers [26, 27] (Fig 1A).
Radiolabeling of 18F-Aptamer
18F-aptamer was synthesized according to previously reported procedures [24] with some
modifications. N-succinimidyl 4-18F-fluorobenzoate (18F-SFB) was synthesized via a three-
step, one-pot method [28–30] by a synthesizer (Tracerlab FXFN, GE Healthcare, Milwaukee,
WI, USA). Purified 18F-SFB (0.78–1.48 GBq) was reconstituted in dimethylformamide. Oligo-
nucleotides were labeled with 18F using click chemistry [31, 32]. Amine-terminated HER2
PET imaging of HER2 aptamer
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aptamer (5–10 nmol in PBS, pH 8.5) was added to the 18F-SFB residue, and the mixture was
stirred for 30 minutes at 37˚C. Subsequently, the mixture was purified by using reverse phase
high performance liquid chromatography (HPLC) with a semi-preparative C18 column
(Xbridge OST C18 10×50 mm, gradient acetonitrile/0.1M TEAA 5:95–95:5 over 20 minutes)
at a flow rate of 5 mL/min, equipped with a UV (254 nm) detector and a radioactivity detector.
The HPLC fraction containing 18F-FB aptamer was diluted with water and passed through a
C18 Sep-Pak cartridge (Waters Corporation, Milford, MA). The labeled aptamer was then
eluted with 500 μL of ethanol and formulated in normal saline for in vivo experiments. The
schematic mechanismof radioisotope- or fluorescence-labeled aptamer is shown in Fig 1B.
Confocal microscopy
BT474 or MDA-MB231 cells were seeded onto coverslips and cultured overnight. The cells,
at> 80% confluence, were carefully washed and then incubated with the fluoro-labeled apta-
mer at a final concentration of 250 nM. After 30 minutes incubation, cells were carefully
washed and mounted on slides on mounting medium containing (4’, 6-diamidino-2-phenylin-
dole) DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). The fluorescent signal was
detected via LSM700 confocal microscopy (Zeiss, Jena, Germany). Excitation wavelength and
emission filters were as follows: fluorescein isothiocyanate (FITC), 488 nm laser line excitation,
emission BP490-555; and DAPI, 405 nm laser line excitation, emission SP490 filter.
Flow cytometry
The specificity of the HER2 aptamer was evaluated with a fluorescence-activated cell sorting
(FACS) LSR II Flow Cytometer System (BD Biosciences, San Jose, CA, USA). BT474 and
Fig 1. The structure of HER2 aptamer. The predicted secondary structure of aptamer SH-1194-35 based on a lowest free energy model (A) and
schematic mechanism (B) of radioisotope- or fluorescence-labeled aptamer.
https://doi.org/10.1371/journal.pone.0211047.g001
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MDA-MB231 cancer cells were seeded onto Petri dishes in complete medium and grown to
80% confluence. Cells were treated with trypsin, washed, and incubated at 4˚C for 30 minutes
with the fluoro-labeled HER2-specific aptamer or antibody (Biolegend, San Diego, CA, USA)
as a control in saline containing 1% fetal bovine serum. After washing, bound aptamer mole-
cules were detected, and cells were analyzed using a fiuorescence-activated cell sorter.
In vivo experiment
Four-week-old female Balb/c nude mice were implanted subcutaneously with 17β-estradiol
pellets (Innovative Research of America, Sarasota, FL, USA) at the dorsal side of the neck, with
dosage release rates sufficient to permit estrogen-dependent tumorigenesis. After a few days,
mice were inoculated subcutaneously with 7 × 106 human breast cancer cells in the axilla.
Tumors were allowed to develop for 3 weeks before imaging studies were performed. PET
images were taken when the tumor was 1 cm or more. The maximal tumor size was 1.7 cm.
Tumor growth was monitored by caliper measurement. Careful observations were be made a
minimum of once daily for the duration of the study. General activity, body condition, hydra-
tion, interaction with cage mates and appearance were carefully observed to assess general
health and well-being. During PET imaging, mouse was observed continuously for the whole
imaging time. Frequency of observation was increased with the appearance of any clinical
signs. The endpoints were selected to minimize the potential pain of the animal according to
ethical issues. The euthanasia was performed when the tumor exceed 2 cm, the body weight
decreased by more than 20%, the ulcer developed, or the condition of the animal appears to be
bad. Humane euthanasia was performed using a carbon dioxide chamber.
Ex vivo biodistribution
BT474 tumor-bearing mice were injected with 18F-labeled HER2 aptamer (7.4 ± 0.2 MBq)
through lateral tail vein and sacrificed at 60 minutes (n = 4) after injection. Twelve tissues
(blood, muscle, heart, lung, spleen, bone, liver, stomach, small intestine, large intestine, kidney,
and tumor) were harvested, washed, weighed, and assayed. Blood samples were obtained by
cardiac puncture, and muscle were dissected from thigh. The radioactivity of each sample was
measured using a gamma counter (PerkinElmer, CA, USA). The uptake of radiotracer in tis-
sues was expressed in counts per minute corrected with decay and normalized to the percent-
age injected dose per gram (%ID/g).
18F-aptamer PET imaging
We intravenously injected radiopharmaceutical-labeled aptamer into mice and performed
PET imaging using a Siemens Inveon PET (Siemens Medical Solutions USA Inc., Knoxville,
TN, USA). The injected dose was 13.7 ± 1.1 MBq (370 ± 30 μCi). A dynamic PET study was
performed for 30 minutes with the following protocol: ten 1- minute images and four 5- min-
utes images. Two static studies were then performed, for 10 minutes each, at 60, 90 and 120
minutes after injection. Semi-quantification of PET signals was performed using AMIDE soft-
ware (SourceForge, New York, NY, USA). The uptake of PET image was quantified based on
Region of interest (ROI) analysis. 3D ROI were drawn around the edge of the tumor or organ
activity by visual inspection. The mean and maximum activities were recorded from the entire
ROI. Uptake analysis was performed to quantify the tracer uptake as the %ID/g in the tumors
as well as in background muscle uptake. Images are presented using a false-color or gray-color
scale that is proportional to tissue concentration (%ID/g) of positron-labeled probe.
PET imaging of HER2 aptamer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211047 January 25, 2019 5 / 14
Statistical analyses
Statistical analyses were performed in SPSS version 22.0 (SPSS Inc., Chicago, Illinois). Inde-
pendent sample t-test were used to analyze the variance of experimental design. Each experi-
ment was repeated at least three times in duplicates, and statistically significant at p<0.05.
Results
Verification of HER2 expression and aptamer affinity for target tumor cells
Western blot and flow cytometry assays were performed to investigate the expression of HER2
in BT474 breast cancer cells. Western blot analysis confirmed overexpression of HER2 in
BT474 and SKBR3 cells, which are known to overexpress HER2 due to gene amplification
[33]. The negative control cell lines, MDA-MB231 and HS578T, showed no signal in the corre-
sponding location (Fig 2).
As seen in Fig 3, HER2 antibody showed highly specific binding to HER2-positive BT474
cancer cells in flow cytometry analysis. Compared to antibody, HER2 aptamer (SH-1194-35)
also had relatively strong binding to BT474 cells, while binding to MDA-MB231 cells was
quite low. In addition, a random DNA oligonucleotide showed no significant binding prefer-
ence for either cell line. These results suggested that the HER2 aptamer preferentially binds to
HER2-positive breast cancer cells, possibly by recognizing the HER2 structure on the surface
of these cells.
Confocal microscopic analysis
The binding of the selected aptamer to cells was further assessed by confocal microscopy (Fig
4). BT474 HER2-positive breast cancer cells were treated with conjugated aptamer. FITC-
labeled SH-1194-35 aptamer was readily visualized on the cell surface, indicating occupation
Fig 2. HER2 expression characteristics as determined by western blotting of human breast cancer cell lines. The BT474 and SK-BR3 cell lines highly expressed
HER2, whereas MDA-MB231 and HS578T cells had no detectable HER2 expression. Beta-actin was used as a loading control.
https://doi.org/10.1371/journal.pone.0211047.g002
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of the HER2 structure on the surface of these cells. The presence of the HER2 aptamer (green)
was visualized along the cell membrane. In contrast, MDA-MB231 cells, the negative control,
showed no significant fluorescence of the aptamer, indicating absence of HER2 expression.
The SH-1194-35 aptamer was found to be able to bind HER2-positive breast cancer cells, with
minimal binding to HER2-negative cells. The HER2 expression could be visualized by fluores-
cence-labeled aptamer.
In vivo PET imaging, biodistribution, and immunohistochemistry
Biodistribution was evaluated in tumor-bearing mice at 1-hour after injection of the 18F-
labeled HER2-specific aptamer. After sacrificing the animal, radioactivity of each organ
including tumor was measured using gamma counter and expressed as %ID/g (Fig 5). Tumor
uptake of the 18F-labeled HER2-specific aptamer was 0.62±0.04 at 1 hour. Biodistribution
study showed that the two major excretory systems of 18F-labeled HER2-specific aptamer are
the kidneys and intestine.
Using animal micro PET, in vivo molecular images of BT474 tumor-bearing mice were
taken at several time points. As seen in Fig 6, 18F-labeled HER2-specific aptamer PET showed
significantly increased uptake into the tumor. In images taken at 120 minutes, the tumor was
clearly labeled by SH-1194-35 aptamer in axial and coronal images (Fig 6A). Physiologic signal
of radioactive tracer into the bowel and bladder was predominant, refiecting the two major
clearance pathways of radiopharmaceuticals.
Fig 3. Flow cytometry analysis of breast cancer cell lines using HER2 antibody and aptamer. (A) Dot plots
representing the fluorescence signals for BT474 (HER2-positive cells), MDA-MB231 (HER2-negative cells) from
monoclonal antibody, and SH-1194-35 aptamer (red) or scrambled random sequence (blue). (B) Flow cytometric
histogram of two cells using antibody, aptamer, and negative control.
https://doi.org/10.1371/journal.pone.0211047.g003
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Fig 6 shows representative images of 18F-labeled HER2 aptamer PET in HER2-positive and
negative tumor-bearing mice. BT474 tumors overexpressing HER2 showed higher radioiso-
tope uptake than HER2-negative MB-MDA231 tumors. For semi-quantitative analysis, total
activity of (nCi) each voxel- or volume-of-interest (VOI) was calculated. Comparison of tumor
uptake between BT474 and MDA-MB231 cells demonstrated significantly in HER2 overex-
pressing BT474 tumors (Fig 6).
Immunohistochemistry confirmed the high expression of HER2 in BT474 tumors and low
expression of HER2 in MDA-MB231 tumors extracted from each mouse group (Fig 7).
Discussion
The primary objective of this study was to investigate tumor-specific PET imaging using radio-
labeled aptamers. In this study, SH-1194-35, a HER2-targeted DNA aptamer, was successfully
PET imaged in vivo. Since its first description in 1990 [1], numerous SELEX methods have
been investigated and many novel aptamers have been developed. Among them, we chose
HER2-targeted DNA aptamers as candidates for imaging agents. Previous studies have dem-
onstrated the utility of HER2 aptamers in inhibiting tumorigenic growth, both by themselves
[19] and by delivering cytotoxic drugs [18]. There are a few reports on the use of aptamers to
image HER2-targeted cancer. Recently, an attempt to apply molecular imaging using a 99mTc-
Fig 4. Confocal microscopic images of selected aptamer binding to HER2-positive cells. (A) BT474, HER2-positive
breast cancer cells were incubated with FITC-labeled aptamer. (B) MDA-MB231 cancer cells were treated with the
same aptamer. (Labeling, blue: DAPI; green: FITC-aptamer).
https://doi.org/10.1371/journal.pone.0211047.g004
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labeled aptamer was reported, describing biodistribution data without images [34]. To our
knowledge, the present study is the first report of HER2-targeted 18F-labeled PET imaging
using specific aptamer. PET images of BT474 tumor-bearing mice showed reliable tumor-to-
background ratios, which implies that the aptamer recognized the HER2 target in vivo.
In this study, flow cytometry and confocal microscopic analysis were performed to verify
target-binding affinity of aptamers. There are many aptamers available for any given specific
target. To determine which aptamer is appropriate for any particular study, assessment of
affinity is required. SH-1194-35, a modified DNA aptamer designed to target HER2, showed
superior performance in in vitro experiments, and thus, we adopted this aptamer for PET
imaging.
Many therapeutic aptamers are being established in clinical trials for pharmaceutical safety
and efficacy [35–38]. Among others, AS1411, a DNA aptamer targeting nucleolin, shows anti-
tumor efficacy against renal cell carcinoma, and has completed a phase 2 trial [39]. Other apta-
mers, like ARC1779, targeting activated von Willebrand Factor (vWF), have verified efficacy
against purpura and thrombotic thrombocytopenic disease. In addition, several RNA aptamer
Fig 5. Biodistribution of 18F-labeled HER2 aptamer. Biodistribution study of 18F-labeled HER2 aptamer in BT474
tumor-bearing mice. Data are expressed as a percentage of injected activity per gram of tissue (%ID/g). Error bars, SD
(N = 4).
https://doi.org/10.1371/journal.pone.0211047.g005
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Fig 6. Representative images of in vivo 18F-labeled HER2-aptamer PET in HER2-positive and negative tumor-bearing mice. (A) HER2 overexpressing BT474
tumor shows increased uptake, compared to the (B) HER2-negative MB-MDA231 tumor. (C) %ID/g of tumor calculated from 18F-labeled HER2 aptamer. The %ID/g of
aptamer in the BT474 tumor were significantly higher than those in the MDA-MD231 tumor.
https://doi.org/10.1371/journal.pone.0211047.g006
Fig 7. Representative staining results from H&E and IHC for HER2 (original magnification 400X).
Immunohistochemically, the BT474 tumor cells (upper row) show strong membranous staining for HER2, compared
to MDA-MB231 cells (lower row).
https://doi.org/10.1371/journal.pone.0211047.g007
PET imaging of HER2 aptamer
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conjugates targeting PSMA [40] or designed to facilitate PSMA-targeted drug delivery [41]
have reinvigorated research in the field. Likewise, due to tremendous translational potential
for aptamers in clinical applications, there are many aptamers and aptamer-based drugs being
evaluated for the treatment of a variety of disorders, involving those of coagulation, cancer,
and inflammation.
Modification of magnetic nanoparticles or fluorescent agents with aptamers might provide
good contrast agents for targeted fluorescence imaging and magnetic resonance imaging
(MRI). Several in vivo MRI studies on tumor-bearing mice demonstrated efficient targeting of
tumors [42, 43]. Since metabolic changes commonly occur before anatomical changes, PET
has a clear diagnostic advantage over conventional anatomical techniques. In addition to its
clinical utility, PET has a wide range of applications in basic research and preclinical arenas.
For example, PET can be used to evaluate novel radiopharmaceuticals, effectiveness of new
therapies, and biodistribution of pharmaceuticals. PET has key strengths in its depth of pene-
tration, excellent sensitivity, quantitative data, and translatability from the pre-clinical to clini-
cal stage [22]. However, there have been only a few studies that have attempted to establish
PET imaging of aptamers. Recently, PET imaging of tenascin-C with a radiolabeled single-
stranded DNA aptamer was reported [24]. A tenascin-C aptamer, labeled with 18F or 64Cu,
demonstrated reliable tumor uptake, compared to a nonspecific scrambled aptamer. However,
comparison with a conventional monoclonal antibody was not undertaken in that study.
The application of aptamers in cancer therapy is emerging and is being extensively studied
at present. Our data suggest its potential for use as a target-specific molecular imaging tool for
determining course of treatment. Aptamers or aptamer-based drugs may provide alternative
options for the treatment of HER2-positive refractory malignancy, since aptamers may use dif-
ferent mechanisms than monoclonal antibodies do to occupy certain target molecules and
may avoid provoking an immune reaction. In addition, because of their highly specific target
affinity and applicability, aptamers might be ideal carriers for drugs or toxins. This has been
demonstrated by Zhe Liu et al [18], who showed that a complex of aptamer and doxorubicin
could selectively deliver doxorubicin to HER2-positive breast cancer cells, with minimal bind-
ing to HER2-negative cells.
There are several limitations inherent in this study. We have not yet determined the bind-
ing mechanism of the HER2 aptamer. Further research is needed to establish the molecular
biologic mechanisms of aptamer. Additional methods may be implemented for PET image
improvement in further studies. Although In vivo PET molecular imaging of BT474 tumor-
bearing mice revealed significant higher uptake of the 18F-labeled HER2 specific aptamer into
the tumor compared to the that of HER2-negative cell tumor (p = 0.033), physiologic bowel
uptake is still predominant in whole body image. In order to eliminate physiologic uptake, a
delayed image with clinically sufficient biologic half-life of a pharmaceutical is mandatory.
One solution may be to perform chemical modification, including adding polyethylene glycol
polymer chains (PEGylation), to aptamer to increase their stability. By attaching stabilizing
material, it will be possible to improve the tumor/background ratio and reduce the bowel
uptake in the delayed image. Also, further research is needed through complementary blocking
and competition experiments. Meanwhile, the F-18 is a PET isotope with many advantages,
but it is produced by cyclotron. Therefore, it is difficult to use in a place where the accessibility
of the cyclotron is poor or the synthesis is not supported.
18F-labeled aptamer facilitated visualization of HER2-expression by in vivo molecular imag-
ing. The PET images using 18F-labeled HER2 aptamer successfully showed target specific
radioisotope uptake in the HER2 overexpressing tumor. These results suggest that radiolabeled
HER2 aptamer may have potential applications in determining treatment strategies or in
applying targeted therapy against HER2-positive breast cancer cells.
PET imaging of HER2 aptamer
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